Surfaxin (sinapultide;dipalmitoylphosphatidylcholine;palmitoyl-oleoyl phosphatidylglycerol;palmitic acid)
Orphan
- Region
- 🇪🇺 EU
- Active substance
- sinapultide;dipalmitoylphosphatidylcholine;palmitoyl-oleoyl phosphatidylglycerol;palmitic acid
- Company
- Pharm Research Associates (UK) Limited
- Status
- Application withdrawn
- Therapeutic area
- Respiratory Distress Syndrome, Newborn
- Designations
- Orphan
- Application
- EMEA/H/C/000625
- Official record
- www.ema.europa.eu
Regulatory milestones
No milestones recorded in the last year.
Follow Surfaxin
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.